Structure-based 3D-QSAR - Merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods

Journal of Molecular Structure: THEOCHEM

Volumn 503, Issue 1-2, 2000, Pages 31-50

  Sippl, W ^a   Holtje H D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

3D QSAR; Drug design

Indexed keywords

BENZYLPIPERAZINE DERIVATIVE; BENZYLPIPERIDINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DIETHYLSTILBESTROL; EDROPHONIUM; ESTROGEN RECEPTOR; HUPERZINE A; LIGAND; MINAPRINE; MORPHOLINE DERIVATIVE; PCS 1050; PIPERIDINE DERIVATIVE; TACRINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BINDING AFFINITY; CALCULATION; DRUG DESIGN; DRUG STRUCTURE; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIMULATION;

EID: 0342368665     PISSN: 01661280     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-1280(99)00361-9     Document Type: Article

References (58)

1. Hansch C., Leo A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. 1995;American Chemical Society, Washington, DC.
2. Kubinyi H. QSAR and 3D-QSAR in drug design. Drug Discovery Today. 2:1997;457-467.
3. Cramer R.D. III, Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110:1988;5959-5967.
4. Kubinyi H. 3D-QSAR in Drug Design. Theory, Methods and Applications. 1993;ESCOM Science Publishers BV, Leiden.
5. Kuntz J.D. Structure-based strategies for drug design and discovery. Science. 257:1992;1078-1082.
6. Kim K. Non-linear dependencies in CoMFA. J. Comput. Aided Mol. Des. 7:1993;71-82.
7. Folkers G., Merz A., Rognan D. CoMFA: scope and limitations. Kubinyi H. 3D-QSAR in Drug Design. Theory, Methods and Applications. 1993;583-618 ESCOM Science Publishers BV, Leiden.
8. Klebe G., Abraham U. On the prediction of binding properties of drug molecules by comparative molecular field analysis. J. Med. Chem. 36:1993;70-80.
9. Van de Waterbeemd H., Testa B., Folkers G. Computer-Assisted Lead Finding and Optimization. Current Tools for Medicinal Chemistry. 1997;Verlag Helvetica Chimica Acta, Basel, Switzerland.
10. Höltje H.-D., Folkers G. Mannhold R., Kubinyi H., Timmerman H. Methods and Principles in Medicinal Chemistry: Vol. 5. Molecular Modeling - Basic Principles and Applications. 1997;VCH Verlags-gesellschaft, Weinheim, Germany.
11. Kramer B., Rarey M., Lengauer T. CASP2 Experiences with docking flexible ligands using FlexX. Proteins, Suppl. 1:1997;221-225.
12. Morris G.M., Goodsell D.S., Huey R., Olson A.J. Distributed automatic docking of flexible ligands to proteins. J. Comput. Aided Mol. Des. 8:1994;243-256.
13. Lybrand T.P. Ligand-protein docking and rational drug design. Curr. Opin. Struct. Biol. 5:1995;224-228.
14. Meng E., Shoichet B.K., Kuntz I.D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 13:1992;505-524.
15. Tame J.R.H. Scoring functions: a view from the bench. J. Comput. Aided Mol. Des. 13:1999;99-108.
16. Böhm H.J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de-novo design or 3D database search programs. J. Comput. Aided Mol. Des. 12:1998;309-323.
17. Böhm H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 8:1994;243-256.
18. Lemmen C., Lengauer T., Klebe G. FLEXS: a method for fast flexible ligand superposition. J. Med. Chem. 41:1998;4502-4520.
19. Waller C.L., Oprea T.I., Giolitti A., Marshall G.R. Three-dimensional QSAR of human immunodeficiency virus (i) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. J. Med. Chem. 36:1993;4152-4160.
20. De Priest S.A., Mayer D., Naylor C.B., Marshall G.R. 3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: a comparison of COMFA models based on deduced and experimentally determined active-site geometries. J. Am. Chem. Soc. 115:1993;5372-5384.
21. Cho S.J., Garsia M.L., Bier J., Tropsha A. Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J. Med. Chem. 39:1996;5064-5071.
22. Pastor M., Cruciani G., Watson K. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantiative structure-activity relationship analysis. J. Med. Chem. 40:1997;4089-4102.
23. Vaz R.J., McLean L.R., Pelton J.T. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxyl]phenyl]-3-(7-amidino-2- naphtyl)-propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis. J. Comput. Aided Mol. Des. 12:1998;99-110.
24. Evans R.M. The Steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
25. E. Von Angerer, The Estrogen Receptor as a Target for Rational Drug Design, Landes, Austin, USA, 1995.
26. Zeelen F.J. Medicinal Chemistry of Steroids. 1990;Elsevier, Amsterdam.
27. Anstead G.M., Carlson K.E., Katzenellenbogen J.A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids. 62:1996;268-303.
28. Höltje H.-D., Dall N. A molecular modelling study on the hormone binding site of the estrogen receptor. Pharmazie. 48:1993;243-246.
29. Lewis D.F.V., Parker M.G., King R.J.B. Molecular modeling of the human estrogen receptor and ligand interaction based on site-directed mutagenesis and amino acid sequence homology. J. Steroid. Biochem. Mol. Biol. 52:1995;55-65.
30. Goldstein R.A., Katzenellenbogen J.A., Luthey-Schulten Z.A., Seielstad D.A., Wolynes P.G. Three-dimensional model for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA. 90:1993;9949-9953.
31. Lemesle-Varloot L., Ojasoo T., Mornon J.P., Raynaud J.P. A Model for the determination of the 3d-spatial distribution of the functions of the hormone-binding domain of receptor that bind 3-keto-4-ene steroids. J. Steroid Bicohem. Mol. Biol. 41:1992;369-388.
32. Wurtz J.M., Egner U., Heinrich N., Moras D., Mueller-Fahrnow A. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationships data. J. Med. Chem. 41:1998;1803-1814.
33. 2-guided region selection approach. J. Med. Chem. 41:1998;2261-2267.
34. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the estrogen receptor. Nature. 389:1997;753-758.
35. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
36. Goodsell D.S., Morris G.M., Olson A.J. Automated docking of flexible ligands: applications of AUTODOCK. J. Mol. Recognit. 9:1996;1-5.
37. Rao M.J., Olson A.J. Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. Prot. Struct. Funct. Gen. 34:1999;173-183.
38. Goodford P.J. A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J. Med. Chem. 28:1985;849-857.
39. Vedani A., Huhta D.W. A new force field for modelling metalloproteins. J. Am. Chem. Soc. 112:1990;269-280.
40. Vedani A., Dunitz J.D. Lone-pair directionality of H-bond potential functions for molecular mechanics calculations: the inhibition of human carbonic anhydrase II by sulfonamides. J. Am. Chem. Soc. 107:1985;7653-7658.
41. Taylor N.R., von Itzstein M. A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase. J. Comput. Aided Mol. Des. 10:1996;233-246.
42. Jiang H., Chen K., Tang Y., Chen J., Li Q., Wang Q., Ji R. Molecular modelling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human α-thrombin. J. Med. Chem. 40:1997;3085-3090.
43. Viswanadhan V.N., Reddy M.R., Wlodawer A., Varney M.D., Weinstein J. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type I protease. J. Med. Chem. 39:1996;705-712.
44. Baroni M., Constantino G., Cruciani G., Riganelli D., Valigli R., Clementi S. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 12:1993;9-20.
45. Cruciani G., Watson K. Comparative molecular field analysis using GRID force field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. 37:1994;2589-2601.
46. Oprea T.I., Garcia A.E. Three-dimensional quantitative structure activity relationships of steroid aromatase inhibitors. J. Comput. Aided Mol. Des. 10:1996;186-200.
47. W. Sippl, Receptor-based three-dimensional quantitative structure-activity relationships of estrogen receptor ligands, J. Comput. Aided. Mol. Des., submitted for publication, 1999.
48. Sippl W., Contreras J.M., Rival Y., Wermuth C.G. Comparative molecular field analysis of aminopyridazine acetylcholinesterase inhibitors. Proceedings of the 12th European Congress on Quantitative Structure-Activity Relationships Copenhagen. 23-28:1998;1998.
49. Parnetti L., Senin U., Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. The way forward. Drugs Future. 53:1997;752-768.
50. Giacobini E. From molecular structure to alzheimer therapy. Jpn. J. Pharmacol. 74:1997;225-241.
51. Brufani M., Filocamo L., Lappa S., Maggi A. New acetylcholinesterase inhibitors. Drugs Future. 22:1997;397-410.
52. Wermuth C.G. Aminopyridazines - an alternative route to potent muscarinic agonists with noccholinergic syndrome. Farmaco, Ed. Sci. 48:1993;253-274.
53. Wermuth C.G., Schlewer G., Bourguignon J.J., Maghioros G., Bouchet M.J., Moire C., Kann J.P., Worms P., Biziere K. 3-Aminopyridazine derivatives with atypical antidepressant serotonergic, and dopaminergic activities. J. Med. Chem. 32:1989;528-537.
54. Wermuth C.G., Contreras J.M., Chayer S., Pinto J., Guilbaud P., Rival Y., Bourguignon J.J. 3-Aminopyridazines as a source of acetylcholinesterase inhibitors. Acta Pharm. Hung. 1996;S3-S8.
55. Contreras J.M., Rival Y., Chayer S., Bourguignon J.J., Wermuth C.G. Aminopyridazines as acetylcholinesterase inhibitors. J. Med. Chem. 42:1999;730-741.
56. Sussman J.L., Silman I. Atomic structure of acetylcholinesterase from torpedo californica: a prototypic acetylcholine-binding protein. Science. 253:1991;872-879.
57. Harel M., Sussman J.L. Quaternary ligand binding to aromatic residues in the active site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA. 90:1993;9031-9035.
58. Raves M.L., Harel M., Pang Y.P., Silman I., Kozikowski A.P., Sussman J.L. Structure of acetylcholinesterase complexed with the nootropic alkaloid huperzine A. Nat. Struct. Biol. 4:1997;57-63.